Growth factors and the development of diabetic nephropathy

Current Diabetes Reports

Volumn 3, Issue 6, 2003, Pages 485-490

  Wolf, Gunter ^a  

^a UNIVERSITY OF HAMBURG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ADVANCED GLYCATION END PRODUCT; AMINOGUANIDINE; CONNECTIVE TISSUE GROWTH FACTOR; GLUCOSE; GROWTH FACTOR; OCTREOTIDE; OSTEOGENIC PROTEIN 1; REACTIVE OXYGEN METABOLITE; SCATTER FACTOR; SOMATOMEDIN; TRANSFORMING GROWTH FACTOR BETA; TRANSFORMING GROWTH FACTOR BETA ANTIBODY; VASCULOTROPIN; VASCULOTROPIN ANTIBODY;

AMADORI REARRANGEMENT; DIABETIC NEPHROPATHY; DISEASE ASSOCIATION; ENZYME MECHANISM; GLOMERULOSCLEROSIS; GLOMERULUS; GLUCOSE TRANSPORT; HOMEOSTASIS; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; KIDNEY BLOOD FLOW; KIDNEY FIBROSIS; KIDNEY HYPERTROPHY; KIDNEY TUBULE ABSORPTION; MOLECULAR MECHANICS; MOUSE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PATHOGENESIS; PLEIOTROPY; PROTEIN EXPRESSION; PROTEIN INDUCTION; PROTEIN MODIFICATION; REVIEW; STREPTOZOCIN DIABETES; THEORY;

EID: 3142723326     PISSN: 15344827     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11892-003-0012-2     Document Type: Review

References (50)

1. Wolf G, Ziyadeh FN: Molecular mechanisms of diabetic renal hypertrophy. Kidney Int 1999, 56:393-405.
2. Wolf G, Chen S, Han DC, Ziyadeh FN: Leptin and renal disease. Am J Kidney Dis 2002, 39:1-11.
3. McGowan TA, Madesh M, Zhu Y, et al.: TGF-beta-induced Ca2+ influx involves the type III IP3 receptor and regulates actin cytoskeleton. Am J Physiol Renal Physiol 2002, 282:F910-F920.
4. Brownlee M: Biochemistry and molecular cell biology of diabetic complications. Nature 2001, 414:813-820.
5. Murphy M, Godson C, Cannon S, et al.: Suppression subtractive hybridization identifies high glucose levels as a stimulus for expression of connective tissue growth factor and other genes in human mesangial cells. J Biol Chem 1999, 274:5830-5834.
6. Flyvbjerg A: Putative pathophysiological role of growth factors and cytokines in experimental diabetic kidney disease. Diabetologia 2000, 43:1205-1223.
7. Gooch JL, Tang Y, Ricono JM, Abboud HE: Insulin-like growth factor-I induces renal cell hypertrophy via a calcineurin-dependent mechanism. J Biol Chem 2001, 276:42492-42500.
8. Lupia E, Elliot SJ, Lenz O, et al.: IGF-1 decreases collagen degradation in diabetic NOD mesangial cells. Implications for diabetic nephropathy. Diabetes 1999, 48:1638-1644.
9. Gruden G, Araf S, Zonca S, et al.: IGF-I induces vascular endothelial growth factor in human mesangial cells via a Src-dependent mechanism. Kidney Int 2003, 63:1249-1255.
10. Cummings EA, Sochett EB, Dekker MG, et al.: Contribution of growth hormone and IGF-I to early diabetic nephropathy in type 1 diabetes. Diabetes 1998, 47:1341-1346.
11. Landau D, Israel E, Rivkis I, et al.: The effect of growth hormone on the development of diabetic kidney disease in rats. Nephrol Dial Transplant 2003, 18:694-702.
12. Sugimoto H, Shikata K, Makino H, et al.: Increased gene expression of insulin-like growth factor-I receptor in experimental diabetic rat glomeruli. Nephron 1996, 72:648-653.
13. Doublier S, Seurin D, Fouqueray B, et al.: Glomerulosclerosis in mice transgenic for human insulin-like growth factor-binding protein-1. Kidney Int 2000, 57:2299-2307.
14. Bellush LL, Doublier S, Holland AN, et al.: Protection against diabetes-induced nephropathy in growth hormone receptor/ binding protein gene-disrupted mice. Endocrinology 2000, 141:163-168.
15. Flyvbjerg A, Bennett WF, Rasch R, et al.: Inhibitory effect of a growth hormone receptor antagonist (G120K-PEG) on renal enlargement, glomerular hypertrophy and urinary albumin excretion in experimental diabetes in mice. Diabetes 1999, 48:377-382.
16. Bak M, Thomsen K, Flyvbjerg A: Effects of the somatostatin analogue octreotide on renal function in conscious diabetic rats. Nephrol Dial Transplant 2001, 16:2002-2007.
17. Raz I, Rubinger D, Popovtzer M, et al.: Octreotide prevents the early increase in renal insulin-like growth factor biding protein 1 in streptozotocin diabetic rats. Diabetes 1998, 47:924-930.
18. Doi T, Striker LJ, Gibson CC, et al.: Glomerular lesions in mice transgenic for growth hormone and insulin-like growth factor-I. Am J Pathol 1990, 137:541-552.
19. Tsuchida KI, Cronin B, Sharma K: Novel aspects of transforming growth factor-beta in diabetic kidney disease. Nephron 2002, 92:7-21.
20. Yamagishi SI, Inagaki Y, Okamoto T, et al.: Advanced glycation end products inhibit de novo protein synthesis and induce TGF-beta overexpression in proximal tubular cells. Kidney Int 2003, 63:464-473.
21. Kang MJ, Ingram A, Ly H, et al.: Effects of diabetes and hypertension on glomerular transforming growth factor-beta receptor expression. Kidney Int 2000, 58:1677-1685.
22. Hong SW, Isono M, Chen S, et al.: Increased glomerular and tubular expression of transforming growth factor beta1, its type II receptor, and activation of the Smad signaling pathway in the db/db mouse. Am J Pathol 2001, 158:1653-1663.
23. Hoffman BB, Sharma K, Zhu Y, Ziyadeh FN: Transcriptional activation of transforming growth factor-beta1 in mesangial cell culture by high glucose concentration. Kidney Int 1998, 58:1107-1116.
24. Weigert C, Sauer U, Brodbeck K, et al.: AP-1 proteins mediate hyperglycemia-induced activation of the human TGF-beta1 promotor in mesangial cells. J Am Soc Nephrol 2000, 11:2007-2016.
25. Poczatek MH, Hugo C, Darley-Usmar V, Murphy-Ullrich JE: Glucose stimulation of transforming growth factor-beta bioactivity in mesangial cells is mediated by thrombospondin-1. Am J Pathol 2000, 157:1353-1363.
26. Lam S, Verhagen NAM, Strutz F, et al.: Glucose-induced fibronectin and collagen type III expression in renal fibroblasts can occur independent of TGF-beta1. Kidney Int 2003, 63:878-888.
27. Zheng F, Fornoni A, Elliot SJ, et al.: Upregulation of type I collagen by TGF-beta in mesangial cells is blocked by PPARgamma activation. Am J Physiol Renal Physiol 2002, 282:F639-F648.
28. Monkawa T, Hiromura K, Wolf G, Shankland SJ: The hypertrophic effect of transforming growth factor-beta is reduced in the absence of cyclin-dependent kinase-inhibitors p21 and p27. J Am Soc Nephrol 2002, 13:1172-1178.
29. Ziyadeh FN, Hoffman BB, Han DC, et al.: Long-term prevention of renal insufficiency, excess matrix gene expression, and glomerular mesangial matrix expansion by treatment with monoclonal antitransforming growth factor-beta antibody in db/db diabetic mice. Proc Natl Acad Sci U S A 2000, 97:8015-8020.
30. Chen S, Iglesias-de la Cruz MC, Jim B, et al.: Reversibility of established diabetic nephropathy by anti-TGF-beta antibodies in db/db mice. Bicohem Biophys Res Commun 2003, 300:16-22.
31. Wang S, Hirscheberg R: BMP7 antagonizes TGF-beta-dependent fibrogenesis in mesangial cells. Am J Physiol Renal Physiol 2003, 284:1006-1013.
32. Riser BL, Denichilo M, Cortes P, et al.: Regulation of connective tissue growth factor activity in cultured rat mesangial cells and its expression in experimental diabetic glomerulosclerosis. J Am Soc Nephrol 2000, 11:25-38.
33. Gore-Hyer E, Shegogue D, Markiewicz M, et al.: TGF-beta and CTGF have overlapping and distinct fibrogenic effects on human renal cells. Am J Physiol Renal Physiol 2002, 283:F707-F716.
34. Weston BS, Wahab NA, Mason RM: CTGF mediates TGF-beta-induced fibronectin matrix deposition by upregulating active alpha5beta1 integrin in human mesangial cells. J Am Soc Nephrol 2003, 14:601-610.
35. Twigg SM, Cao Z, McLennan SV, et al.: Renal connective tissue growth factor induction in experimental diabetes is prevented by aminoguanidine. Endocrinology 2002, 143:4907-4915.
36. Wahab NA, Yevdokimova N, Weston BS, et al.: Role of connective tissue growth factor in the pathogenesis of diabetic nephropathy. Biochem J 2001, 359:77-87.
37. Wahab NA, Wqeston BS, Roberts T, Mason RM: Connective tissue growth factor and regulation of the mesangial cell cycle: role in cellular hypertrophy. J Am Soc Nephrol 2002, 13:2437-2445.
38. Inoue T, Okada H, Kobayashi T, et al.: Hepatocyte growth factor counteracts transforming growth factor-beta1, through attenuation of connective tissue growth factor induction, and prevents renal fibrogenesis in 5/6 nephrectomized mice. FASEB J 2003, 17:268-270.
39. Liu Y, Tolbert EM, Sun AM, Dworkin LD: In vivo and in vitro evidence for increased expression of HGF receptor in kidney of diabetic rat. Am J Physiol Renal Physiol 1996, 271:F1202-F1210.
40. Neufeld G, Cohen T, Gegrinovitch S, Poltorak Z: Vascular endothelial growth factor (VEGF) and its receptors. FASEB J 1999, 13:9-22.
41. Cooper ME, Vranes D, Youssef S, et al.: Increased renal expression of vascular endothelial growth factor (VEGF) and its receptor VEGFR-2 in experimental diabetes. Diabetes 1999, 48:2229-2239.
42. Masuda Y, Shimizu A, Mori T, et al.: Vascular endothelial growth factor enhances glomerular capillary repair and accelerates resolution of experimentally induced glomerulonephritis. Am J Pathol 2001, 159:599-608.
43. El Awad B, Kreft B, Wolber EM, et al.: Hypoxia and interleukin-1beta stimulate vascular endothelial growth factor production in human proximal tubular cells. Kidney Int 2000, 59:43-50.
44. Iglesias-de la Cruz M, Ziyadeh FN, Isono M, et al.: Effects of high glucose and TGF-beta1 on the expression of collagen IV and vascular endothelial growth factor in mouse podocytes. Kidney Int 2002, 62:901-913.
45. Wendt TM, Tanji N, Guo J, et al.: RAGE drives the development of glomerulosclerosis and implicates podocyte activation in the pathogenesis of diabetic nephropathy. Am J Pathol 2003, 162:1123-1137.
46. Tsuchida K, Makita Z, Yamagishi S, et al.: Suppression of transforming growth factor beta and vascular endothelial growth factor in diabetic nephropathy in rats by a novel advanced glycation end product inhibitor, OPB-9195. Diabetologia 1999, 42:579-588.
47. De Vriese AS, Tilton RG, Elger M, et al.: Antibodies against vascular endothelial growth factor improve early renal dysfunction in experimental diabetes. J Am Soc Nephrol 2001, 12:993-1000.
48. Flyvbjerg A, Dahnaes-Hansen F, De Vriese AS, et al.: Amelioration of long-term renal changes in obese type diabetic mice by a neutralizing vascular endothelial growth factor antibody. Diabetes 2002, 51:3090-3094.
49. Senthil D, Choudhury GG, McLaurin C, Kasinath BS: Vascular endothelial growth factor induces protein synthesis in renal epithelial cells: a potential role in diabetic nephropathy. Kidney Int 2003, 64:468-479.
50. Sugimoto H, Hamann Y, Charytan D, et al.: Neutralization of circulating vascular endothelial growth factor (VEGF) by anti-VEGF antibodies and soluble VEGF receptor 1 (sFlt-1) induces proteinuria. J Biol Chem 2003, 278:12605-12608.